Long-term Immunogenicity of Hepatitis A Vaccination in Adults Receiving Immunosuppressive Therapy and Adults Living With HIV: Three-year Follow-up of a Prospective Cohort Study.

ABSTRACT:

Background

Hepatitis A (hepA) vaccination generates long-lasting protection against hepA in healthy adults. However, the duration of protection in immunocompromised patients (ICPs), such as people living with HIV (PLWH) and patients on immunosuppressive therapy, is uncertain.

Methods

This 3-year follow-up study of a prospective cohort assessed hepA antibodies in PLWH, patients on immunosuppressive therapy, and controls after completing a full hepA vaccination series. Three years later (Y3), serum samples were collected in 88/150 (59%) of original participants. The primary outcome was the seroprotection rate (SPR) at Y3, defined as the proportion of participants with hepA antibodies ≥20 mIU/mL. Secondary outcomes included seroreversion rates, defined as the proportion of thos

SUBMITTER: Schnyder JL 

PROVIDER: S-EPMC12448379 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature